Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
Trial ID or NCT#
The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
- - Previously treated recurrent CLL - Measurable lymphadenopathy - Requires therapy for CLL - Has experienced CLL progression < 36 months since the completion of the last prior therapy Key
- - Recent history of a major non-CLL malignancy - Evidence of an ongoing infection - CLL refractory to bendamustine - Concurrent participation in another therapeutic clinical trial NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToCCTO
Go Back To The Trial